IL-4 and IL-13 are among main cytokines involved in Th2 driven immune response (33, 34); blocking IL-4 and IL-13 with dupilumab may cause increased risk of eye infections (conjuntivitis, blepharitis, cheratitis) and oral herpes (35). This evidence concerns the gene IL4 and blepharitis.